Elicio Historical Financial Ratios

ELTX Stock

4.88 0.20 3.94%

Elicio Therapeutics is recently reporting on over 84 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 3.89 or Days Sales Outstanding of 10.59 will help investors to properly organize and evaluate Elicio Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elicio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

About Elicio Financial Ratios Analysis

Elicio TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Elicio Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Elicio financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Elicio Therapeutics history.

Elicio Therapeutics Financial Ratios Chart

At this time, Elicio Therapeutics' PTB Ratio is fairly stable compared to the past year. PB Ratio is likely to rise to 3.89 in 2024, whereas Price To Sales Ratio is likely to drop 0.57 in 2024.

Price To Sales Ratio Days Sales Outstanding Average Payables Payables Turnover Earnings Yield Debt To Equity

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Elicio Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Elicio Therapeutics sales, a figure that is much harder to manipulate than other Elicio Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Earnings Yield

The inverse of the price-to-earnings ratio, representing the percentage of each dollar invested in the stock that was earned by the company.

Debt To Equity

A measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets.

Most ratios from Elicio Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Elicio Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elicio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.At this time, Elicio Therapeutics' PTB Ratio is fairly stable compared to the past year. PB Ratio is likely to rise to 3.89 in 2024, whereas Price To Sales Ratio is likely to drop 0.57 in 2024.

	2023	2024 (projected)
Graham Number	18.77	17.83
Receivables Turnover	33.89	17.01

Graham Number Receivables Turnover

Elicio Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		-0.46	-0.36	-0.35	-0.32	-0.32	-0.17	0.42	-0.46	0.93	-0.32	0.3	-0.15	-0.28	-0.42	-0.23	-0.18	0.44	-0.35	-0.88	-0.37	-0.41	-0.87	-0.2	-0.33	0.25
Ptb Ratio	-0.46		-0.22	-0.25	-0.25	-0.26	0.08	-0.17	1.0	-0.47	-0.25	-0.98	0.35	-0.27	0.36	-0.2	0.23	-0.07	-0.25	0.17	-0.4	-0.01	0.15	0.8	-0.17	-0.96
Days Sales Outstanding	-0.36	-0.22		1.0	0.92	0.93	-0.19	-0.64	-0.22	-0.15	0.92	0.26	-0.4	0.91	0.15	0.66	-0.18	-0.56	0.96	0.7	0.88	0.88	0.71	-0.62	0.97	0.4
Book Value Per Share	-0.35	-0.25	1.0		0.95	0.96	-0.22	-0.61	-0.25	-0.15	0.95	0.29	-0.44	0.94	0.14	0.72	-0.22	-0.52	0.98	0.68	0.88	0.84	0.7	-0.65	0.96	0.42
Free Cash Flow Yield	-0.32	-0.25	0.92	0.95		1.0	-0.2	-0.58	-0.25	-0.13	1.0	0.29	-0.41	1.0	0.12	0.9	-0.2	-0.5	0.99	0.64	0.84	0.73	0.65	-0.63	0.88	0.42
Operating Cash Flow Per Share	-0.32	-0.26	0.93	0.96	1.0		-0.2	-0.58	-0.26	-0.13	1.0	0.3	-0.42	1.0	0.12	0.89	-0.2	-0.5	0.99	0.65	0.85	0.74	0.66	-0.63	0.89	0.43
Average Payables	-0.17	0.08	-0.19	-0.22	-0.2	-0.2		-0.16	0.08	-0.07	-0.2	-0.06	0.5	-0.21	0.16	-0.15	0.45	-0.27	-0.2	0.14	0.14	-0.05	0.14	0.44	-0.18	-0.04
Capex To Depreciation	0.42	-0.17	-0.64	-0.61	-0.58	-0.58	-0.16		-0.17	0.1	-0.58	0.14	-0.41	-0.58	0.06	-0.43	-0.6	0.96	-0.59	-0.7	-0.57	-0.9	-0.71	-0.03	-0.77	-0.03
Pb Ratio	-0.46	1.0	-0.22	-0.25	-0.25	-0.26	0.08	-0.17		-0.47	-0.25	-0.98	0.35	-0.27	0.36	-0.2	0.23	-0.07	-0.25	0.17	-0.4	-0.01	0.15	0.8	-0.17	-0.96
Ev To Sales	0.93	-0.47	-0.15	-0.15	-0.13	-0.13	-0.07	0.1	-0.47		-0.13	0.31	0.01	-0.08	-0.34	-0.08	0.03	0.11	-0.15	-0.68	-0.15	-0.12	-0.66	-0.21	-0.07	0.33
Free Cash Flow Per Share	-0.32	-0.25	0.92	0.95	1.0	1.0	-0.2	-0.58	-0.25	-0.13		0.29	-0.41	1.0	0.12	0.9	-0.2	-0.5	0.99	0.64	0.84	0.73	0.65	-0.63	0.88	0.43
Roic	0.3	-0.98	0.26	0.29	0.29	0.3	-0.06	0.14	-0.98	0.31	0.29		-0.33	0.3	-0.28	0.23	-0.2	0.02	0.3	-0.02	0.47	0.04	-0.01	-0.79	0.21	0.98
Inventory Turnover	-0.15	0.35	-0.4	-0.44	-0.41	-0.42	0.5	-0.41	0.35	0.01	-0.41	-0.33		-0.41	-0.11	-0.31	0.96	-0.53	-0.43	0.1	-0.28	0.04	0.1	0.73	-0.22	-0.29
Net Income Per Share	-0.28	-0.27	0.91	0.94	1.0	1.0	-0.21	-0.58	-0.27	-0.08	1.0	0.3	-0.41		0.09	0.91	-0.19	-0.49	0.99	0.61	0.82	0.71	0.62	-0.63	0.87	0.43
Days Of Inventory On Hand	-0.42	0.36	0.15	0.14	0.12	0.12	0.16	0.06	0.36	-0.34	0.12	-0.28	-0.11	0.09		0.09	-0.25	0.03	0.14	0.31	0.16	0.01	0.32	0.19	0.09	-0.27
Payables Turnover	-0.23	-0.2	0.66	0.72	0.9	0.89	-0.15	-0.43	-0.2	-0.08	0.9	0.23	-0.31	0.91	0.09		-0.15	-0.38	0.84	0.47	0.63	0.44	0.48	-0.48	0.61	0.33
Average Inventory	-0.18	0.23	-0.18	-0.22	-0.2	-0.2	0.45	-0.6	0.23	0.03	-0.2	-0.2	0.96	-0.19	-0.25	-0.15		-0.71	-0.21	0.24	-0.07	0.27	0.24	0.55	0.01	-0.13
Capex To Revenue	0.44	-0.07	-0.56	-0.52	-0.5	-0.5	-0.27	0.96	-0.07	0.11	-0.5	0.02	-0.53	-0.49	0.03	-0.38	-0.71		-0.51	-0.72	-0.57	-0.84	-0.73	-0.06	-0.69	-0.15
Cash Per Share	-0.35	-0.25	0.96	0.98	0.99	0.99	-0.2	-0.59	-0.25	-0.15	0.99	0.3	-0.43	0.99	0.14	0.84	-0.21	-0.51		0.68	0.87	0.78	0.69	-0.64	0.92	0.43
Pocfratio	-0.88	0.17	0.7	0.68	0.64	0.65	0.14	-0.7	0.17	-0.68	0.64	-0.02	0.1	0.61	0.31	0.47	0.24	-0.72	0.68		0.7	0.74	1.0	-0.1	0.7	0.09
Interest Coverage	-0.37	-0.4	0.88	0.88	0.84	0.85	0.14	-0.57	-0.4	-0.15	0.84	0.47	-0.28	0.82	0.16	0.63	-0.07	-0.57	0.87	0.7		0.74	0.72	-0.57	0.85	0.59
Capex To Operating Cash Flow	-0.41	-0.01	0.88	0.84	0.73	0.74	-0.05	-0.9	-0.01	-0.12	0.73	0.04	0.04	0.71	0.01	0.44	0.27	-0.84	0.78	0.74	0.74		0.76	-0.3	0.95	0.21
Pfcf Ratio	-0.87	0.15	0.71	0.7	0.65	0.66	0.14	-0.71	0.15	-0.66	0.65	-0.01	0.1	0.62	0.32	0.48	0.24	-0.73	0.69	1.0	0.72	0.76		-0.12	0.72	0.11
Days Payables Outstanding	-0.2	0.8	-0.62	-0.65	-0.63	-0.63	0.44	-0.03	0.8	-0.21	-0.63	-0.79	0.73	-0.63	0.19	-0.48	0.55	-0.06	-0.64	-0.1	-0.57	-0.3	-0.12		-0.52	-0.81
Income Quality	-0.33	-0.17	0.97	0.96	0.88	0.89	-0.18	-0.77	-0.17	-0.07	0.88	0.21	-0.22	0.87	0.09	0.61	0.01	-0.69	0.92	0.7	0.85	0.95	0.72	-0.52		0.37
Roe	0.25	-0.96	0.4	0.42	0.42	0.43	-0.04	-0.03	-0.96	0.33	0.43	0.98	-0.29	0.43	-0.27	0.33	-0.13	-0.15	0.43	0.09	0.59	0.21	0.11	-0.81	0.37

Click cells to compare fundamentals

Elicio Therapeutics Account Relationship Matchups

Elicio Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	(1.38)	(0.98)	(0.25)	(0.18)	3.71	3.89
Book Value Per Share	(4.28)	(6.03)	(23.29)	(32.95)	2.25	2.14
Free Cash Flow Yield	(0.2)	(0.35)	(1.3)	(1.25)	(0.78)	(0.74)
Operating Cash Flow Per Share	(1.14)	(2.05)	(7.48)	(7.15)	(6.47)	(6.14)
Pb Ratio	(1.38)	(0.98)	(0.25)	(0.18)	3.71	3.89
Free Cash Flow Per Share	(1.2)	(2.07)	(7.65)	(7.37)	(6.48)	(6.16)
Roic	0.36	0.32	0.42	0.26	(3.14)	(2.99)
Net Income Per Share	(1.5)	(1.93)	(8.25)	(9.1)	(6.96)	(6.61)
Payables Turnover	2.15	1.1	0.73	0.38	0.27	0.25
Cash Per Share	0.84	1.84	2.9	1.99	2.55	2.42
Pocfratio	(5.16)	(2.87)	(0.79)	(0.82)	(1.29)	(1.35)
Pfcf Ratio	(4.91)	(2.84)	(0.77)	(0.8)	(1.29)	(1.35)
Days Payables Outstanding	170.14	331.45	497.25	968.61	1.4K	1.4K
Income Quality	0.76	1.06	0.91	0.79	0.93	1.55
Ev To Operating Cash Flow	(4.53)	(2.0)	(0.89)	(0.88)	(1.11)	(1.05)
Pe Ratio	(3.92)	(3.06)	(0.71)	(0.65)	(1.2)	(1.26)
Return On Tangible Assets	(1.39)	(0.8)	(1.78)	(1.24)	(1.3)	(1.36)
Ev To Free Cash Flow	(4.3)	(1.98)	(0.87)	(0.86)	(1.1)	(1.05)
Earnings Yield	(0.26)	(0.33)	(1.4)	(1.54)	(0.83)	(0.79)
Net Debt To E B I T D A	0.15	0.94	(0.0485)	(0.0563)	0.18	0.17
Current Ratio	4.15	4.67	0.55	1.56	1.67	2.78
Tangible Book Value Per Share	(4.28)	(6.03)	(23.29)	(32.95)	2.25	2.14
Graham Number	12.04	16.17	65.76	82.13	18.77	17.83
Shareholders Equity Per Share	(4.28)	(6.03)	(23.29)	(32.95)	2.25	2.14

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity	Operating Cycle
Cash Conversion Cycle

Elicio Historical Financial Ratios

About Elicio Financial Ratios Analysis

Elicio Therapeutics Financial Ratios Chart

Price To Sales Ratio

Average Payables

Payables Turnover

Earnings Yield

Debt To Equity

Elicio Therapeutics fundamentals Correlations

Elicio Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Elicio Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Elicio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Book Value Per Share	+ 1.0	Days Sales Outstanding
Operating Cash Flow Per Share	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Free Cash Flow Yield
Net Income Per Share	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share

Roic	- 0.98	Pb Ratio
Roic	- 0.98	Ptb Ratio
Roe	- 0.96	Pb Ratio
Roe	- 0.96	Ptb Ratio
Capex To Operating Cash Flow	- 0.9	Capex To Depreciation
Pocfratio	- 0.88	Price To Sales Ratio